Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Share-based Compensation (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Share-based Compensation data on record, last reported at $7.4 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 227.37% year-over-year to $7.4 million; the TTM value through Dec 2025 reached $10.0 million, up 47.53%, while the annual FY2025 figure was $10.0 million, 47.53% up from the prior year.
  • Share-based Compensation reached $7.4 million in Q4 2025 per CTNM's latest filing, up from $2.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.4 million in Q4 2025 and bottomed at -$2.5 million in Q2 2025.
  • Average Share-based Compensation over 3 years is $1.6 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: soared 380.29% in 2024, then crashed 265.26% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $759000.0 in 2023, then soared by 196.57% to $2.3 million in 2024, then soared by 227.37% to $7.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $7.4 million in Q4 2025, $2.6 million in Q3 2025, and -$2.5 million in Q2 2025.